• Cartesian Therapeutics Inc RNAC.OQ RNAC.O is expected to show a fall in quarterly revenue when it reports results on March 5 (estimated) for the period ending December 31 2024

• The Frederick Maryland-based company is expected to report a 98.7% decrease in revenue to $103.75 thousand from $8.27 million a year ago, according to the mean estimate from 8 analysts, based on LSEG data.

• ​LSEG's mean analyst estimate for Cartesian Therapeutics Inc is for a loss of 80 cents per share.

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."

• The mean earnings estimate of analysts was unchanged in the last three months. ​

• Wall Street's median 12-month price target for Cartesian Therapeutics Inc is $41.00​, above​ its last closing price of $18.84. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

This summary was machine generated March 3 at 13:32 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)